Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides

Nucleic Acids Research

Volumn 39, Issue 8, 2011, Pages 3350-3362

  Floquet, Célia ^a,b   Deforges, Jules ^a,b   Rousset, Jean Pierre ^a,b   Bidou, Laure ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; MESSENGER RNA; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOP CODON; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

AMIKACIN; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CODON, NONSENSE; GENES, P53; GENTAMICINS; HUMANS; MICE; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955588050     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq1277     Document Type: Article

References (58)

1. Burke, J.F. and Mogg, A.E. (1985) Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res., 13, 6265-6272.
2. Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. and Sweeney, H.L. (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest., 104, 375-381. (Pubitemid 29534321)
3. Bedwell, D.M., Kaenjak, A., Benos, D.J., Bebok, Z., Bubien, J.K., Hong, J., Tousson, A., Clancy, J.P. and Sorscher, E.J. (1997) Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med., 3, 1280-1284. (Pubitemid 27508832)
4. Linde, L. and Kerem, B. (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet., 24, 552-563.
5. Zingman, L.V., Park, S., Olson, T.M., Alekseev, A.E. and Terzic A. (2007) Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin. Pharmacol. Ther., 81, 99-103. (Pubitemid 46050873)
6. Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., Bdolah-Abram, T., Bebok, Z., Shushi, L. et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med., 349, 1433-1441. (Pubitemid 37211058)
7. Clancy, J.P., Bebok, Z., Ruiz, F., King, C., Jones, J., Walker, L., Greer, H., Hong, J., Wing, L., Macaluso, M. et al. (2001) Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med., 163, 1683-1692. (Pubitemid 32578776)
8. Wagner, K.R., Hamed, S., Hadley, D.W., Gropman, A.L., Burstein, A.H., Escolar, D.M., Hoffman, E.P. and Fischbeck, K.H. (2001) Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol., 49, 706-711. (Pubitemid 32530236)
9. Politano, L., Nigro, G, Nigro, V., Piluso, G, Papparella, S., Paciello, O. and Comi, L.I. (2003) Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol., 22, 15-21. (Pubitemid 36966404)
10. Malik, V., Rodino-Klapac, L.R., Viollet, L., Wall, C., King, W., Al-Dahhak, R., Lewis, S., Shilling, C.J., Kota, J., Serrano-Munuera, C. et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol., 67, 771-780.
11. Sermet-Gaudelus, I., Renouil, M., Fajac, A., Bidou, L., Parbaille, B., Pierrot, S., Davy, N., Bismuth, E., Reinert, P., Lenoir, G et al. (2007) In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med., 5, 5.
12. Giaccia, A J. and Kastan, M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12, 2973-2983. (Pubitemid 28469299)
13. Wagner, A.J., Kokontis, J.M. and Hay, N. (1994) Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability ofp53 to induce p21waf1/cip1. Genes Dev., 8, 2817-2830.
14. Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E. and Jacks, T. (1994) p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810. (Pubitemid 24359290)
15. El-Deiry, W.S. (2003) The role ofp53 in chemosensitivity and radiosensitivity. Oncogene, 22, 7486-7495.
16. Lowe, S.W., Ruley, H.E., Jacks, T. and Housman, D.E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967. (Pubitemid 23289454)
17. Takahashi, T., Carbone, D., Nau, M.M., Hida, T., Linnoila, I., Ueda, R. and Minna, J.D. (1992) Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res., 52, 2340-2343.
18. Casey, G, Lo-Hsueh, M., Lopez, M.E., Vogelstein, B. and Stanbridge, E.J. (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene, 6, 1791-1797. (Pubitemid 21924011)
19. Chen, X., Ko, L.J., Jayaraman, L. and Prives, C. (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev., 10, 2438-2451. (Pubitemid 26341879)
20. Roth, JA. (2006) Adenovirus p53 gene therapy. Expert. Opin. Biol. Ther., 6, 55-61. (Pubitemid 43049346)
21. Peng, Z. (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther., 16, 1016-1027. (Pubitemid 41324561)
22. Selivanova, G (2010) Therapeutic targeting ofp53 by small molecules. Semin. Cancer Biol., 20, 46-56.
23. Wang, Z. and Sun, Y. (2010) Targeting p53 for novel anticancer therapy. Transl. Oncol., 3, 1-12.
24. Bykov, V.J., Issaeva, N., Shilov A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K.G and Selivanova, G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med., 8, 282-288. (Pubitemid 34250107)
25. Tang, X., Zhu, Y., Han, L., Kim, A.L., Kopelovich, L., Bickers, D.R. and Athar, M. (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J. Clin. Invest., 117, 3753-3764. (Pubitemid 350224086)
26. Magrini, R., Russo, D., Ottaggio, L., Fronza, G., Inga, A. and Menichini, P. (2008) PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J. Cell Biochem., 104, 2363-2373.
27. Zache, N., Lambert, J.M., Wiman, K.G. and Bykov, V.J. (2008) PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol., 30, 411-418.
28. Bidou, L., Hatin, I., Perez, N., Allamand, V., Panthier, J.J. and Rousset, J.P. (2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther., 11, 619-627. (Pubitemid 38455980)
29. Wang, C.S., Goulet, F., Lavoie, J., Drouin, R., Auger, F., Champetier, S., Germain, L. and Tetu, B. (2000) Establishment and characterization of a new cell line derived from a human primary breast carcinoma. Cancer Genet. Cytogenet., 120, 58-72. (Pubitemid 30410778)
30. Bidou, L., Stahl, G, Hatin, I., Namy, O., Rousset, J.P. and Farabaugh, P.J. (2000) Nonsense-mediated decay mutants do not affect programmed-1 frameshifting. RNA, 6, 952-961. (Pubitemid 30471133)
31. Howard, M.T., Anderson, C.B., Fass, U., Khatri, S., Gesteland, R.F., Atkins, J.F. and Flanigan, K.M. (2004) Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann. Neurol., 55, 422-426. (Pubitemid 38269595)
32. Allamand, V., Bidou, L., Arakawa, M., Floquet, C., Shiozuka, M., Paturneau-Jouas, M., Gartioux, C., Butler-Browne, GS., Mouly, V., Rousset, J.P. et al. (2008) Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. J. Gene Med., 10, 217-224. (Pubitemid 351267163)
33. Salvatori, F., Breveglieri, G, Zuccato, C., Finotti, A., Bianchi, N., Borgatti, M., Feriotto, G, Destro, F., Canella A., Brognara, E. et al. (2009) Production of beta-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous beta(0)39 thalassemia patients. Am. J. Hematol., 84, 720-728.
34. Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G, Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev., 19, 2122-2137. (Pubitemid 41330315)
35. Stagliano, K.E., Carchman, E. and Deb, S. (2003) Real-time polymerase chain reaction quantitation of relative expression of genes modulated by p53 using SYBR Green I. Methods Mol. Biol., 234, 73-91.
36. Rowe, S.M. and Clancy, J.P. (2009) Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. Bio Drugs, 23, 165-174.
37. Keeling, K.M. and Bedwell, D.M. (2002) Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med., 80, 367-376. (Pubitemid 34775375)
38. Zilberberg, A., Lahav, L. and Rosin-Arbesfeld, R. (2010) Restoration of APC gene function in colorectal cancer cells by aminoglycoside-and macrolide-induced read-through of premature termination codons. Gut, 59, 496-507.
39. Howard, M.T., Shirts, B.H., Petros, L.M., Flanigan, K.M., Gesteland, R.F. and Atkins, J.F. (2000) Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol., 48, 164-169. (Pubitemid 30617034)
40. Manuvakhova, M., Keeling, K. and Bedwell, D.M. (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA, 6, 1044-1055. (Pubitemid 30471140)
41. Bellais, S., Le Goff, C., Dagoneau, N., Munnich A. and Cormier-Daire, V. (2010) In vitro readthrough of termination codons by gentamycin in the Stuve-Wiedemann Syndrome. Eur. J. Hum. Genet., 18, 130-132.
42. Nicholson, P., Yepiskoposyan, H., Metze, S., Zamudio Orozco, R., Kleinschmidt, N. and Muhlemann, O. (2010) Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol. Life Sci., 67, 677-700.
43. Kuzmiak, HA. and Maquat, L.E. (2006) Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol. Med., 12, 306-316. (Pubitemid 44094291)
44. Muhlemann, O. (2008) Recognition of nonsense mRNA: towards a unified model. Biochem. Soc Trans., 36, 497-501. (Pubitemid 351850181)
45. Losson, R. and Lacroute, F. (1979) Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad. Sci. USA, 76, 5134-5137. (Pubitemid 10231832)
46. Keeling, K.M., Lanier, J., Du, M., Salas-Marco, J., Gao, L., Kaenjak-Angeletti A. and Bedwell, D.M. (2004) Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. RNA, 10, 691-703. (Pubitemid 38405947)
47. Moriarty, P.M., Reddy, C.C. and Maquat, L.E. (1998) Selenium deficiency reduces the abundance of mRNA for Se-dependent glutathione peroxidase 1 by a UGA-dependent mechanism likely to be nonsense codon-mediated decay of cytoplasmic mRNA. Mol. Cell. Biol., 18, 2932-2939. (Pubitemid 28183462)
48. Weiss, S.L. and Sunde, RA. (1998) Cis-acting elements are required for selenium regulation of glutathione peroxidase-1 mRNA levels. RNA, 4, 816-827. (Pubitemid 28317829)
49. Mingeot-Leclercq, M.P. and Tulkens, P.M. (1999) Aminoglycosides: nephrotoxicity. Antimicrob. Agents Chemother., 43, 1003-1012. (Pubitemid 29214718)
50. Guthrie, O.W. (2008) Aminoglycoside induced ototoxicity. Toxicology, 249, 91-96.
51. Yang, C., Feng, J., Song, W., Wang, J., Tsai, B., Zhang, Y., Scaringe, WA., Hill, K.A., Margaritis, P., High, KA. et al. (2007) A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin. Proc Natl Acad. Sci. USA, 104, 15394-15399. (Pubitemid 47502928)
52. Takamoto, K., Kawada, M., Ikeda, D. and Yoshida, M. (2005) Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C Biochim. Biophys. Acta, 1722, 247-253. (Pubitemid 40354163)
53. Du, M., Keeling, K.M., Fan, L., Liu, X. and Bedwell, D.M. (2009) Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J. Biol. Chem., 284, 6885-6892.
54. Nudelman, I., Glikin, D., Smolkin, B., Hainrichson, M., Belakhov, V. and Baasov, T. (2010) Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg. Med. Chem., 18, 3735-3746.
55. Welch, E.M., Barton, E.R., Zhuo, J., Tomizawa, Y., Friesen, W.J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C.R., Hwang, S. et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature, 447, 87-91. (Pubitemid 46685839)
56. Du, M., Liu, X., Welch, E.M., Hirawat, S., Peltz, S.W. and Bedwell, D.M. (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad. Sci. USA, 105, 2064-2069. (Pubitemid 351439465)
57. Hamed, SA. (2006) Drug evaluation: PTC-124-a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs, 9, 783-789. (Pubitemid 44756118)
58. Sermet-Gaudelus, I., Boeck, K.D., Casimir, G.J., Vermeulen, F., Leal, T., Mogenet, A., Roussel, D., Fritsch, J., Hanssens, L., Hirawat, S. et al. (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med., 182, 1262-1272.